These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22393083)

  • 21. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer.
    Hoque A; Menter DG; Sahin AA; Sneige N; Lippman SM
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):153-4. PubMed ID: 11219775
    [No Abstract]   [Full Text] [Related]  

  • 22. [Ductal carcinoma in situ of the breast].
    Rueda Domínguez A; Alonso Muñoz MC; Gómez Gómez A; Ojeda González B
    Med Clin (Barc); 1993 Oct; 101(14):548-56. PubMed ID: 8231402
    [No Abstract]   [Full Text] [Related]  

  • 23. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.
    Ray PS; Bagaria SP; Wang J; Shamonki JM; Ye X; Sim MS; Steen S; Qu Y; Cui X; Giuliano AE
    Ann Surg Oncol; 2011 Dec; 18(13):3839-47. PubMed ID: 21424368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of ductal carcinoma in situ of the breast. Provincial Breast Cancer Disease Site Group.
    Wright JR; Whelan TJ; McCready DR; O'Malley FP
    Cancer Prev Control; 1998 Dec; 2(6):312-9. PubMed ID: 10470463
    [No Abstract]   [Full Text] [Related]  

  • 25. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
    Bussen S; Rempen A; Caffier H
    Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New challenges of personalized therapy for breast cancer to pathologists].
    Zhong X; Luo T; Zheng H; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):219-21. PubMed ID: 24915809
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
    Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
    Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic relevance of estimates of proliferative activity in early breast cancer.
    Heatley MK; Maxwell P; Whiteside C; Ewing P; Toner PG
    Histopathology; 2005 Jan; 46(1):110-1. PubMed ID: 15656896
    [No Abstract]   [Full Text] [Related]  

  • 31. Update: NCCN breast cancer clinical practice guidelines.
    Carlson RW; Edge SB
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-1-4. PubMed ID: 23570090
    [No Abstract]   [Full Text] [Related]  

  • 32. Pathological definition of triple negative breast cancer.
    Viale G; Bottiglieri L
    Eur J Cancer; 2009 Sep; 45 Suppl 1():5-10. PubMed ID: 19775600
    [No Abstract]   [Full Text] [Related]  

  • 33. A perimenopausal woman with a small, ER/HER2-positive, node-negative breast cancer.
    Brooks G; Borges V; Singh M; Rabinovitch R; Finlayson C; Elias A
    Oncology (Williston Park); 2008 Oct; 22(11):1270-6. PubMed ID: 18980024
    [No Abstract]   [Full Text] [Related]  

  • 34. [Detection and treatment of ductal carcinoma of the breast].
    Semiglazov VV; Tabagua TT; Matsko DE
    Vopr Onkol; 2011; 57(6):699-701. PubMed ID: 22416383
    [No Abstract]   [Full Text] [Related]  

  • 35. Common questions about ductal carcinoma in situ.
    Dell DD
    Am J Nurs; 1997 May; 97(5):61-3, 65-6. PubMed ID: 9155799
    [No Abstract]   [Full Text] [Related]  

  • 36. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
    Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
    Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of the proliferation rate on the course of node negative breast carcinoma].
    Mitze M; Weikel W; Brumm C; Lippold R; Knapstein PG
    Geburtshilfe Frauenheilkd; 1995 Jun; 55(6):299-305. PubMed ID: 7657137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy.
    Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y
    Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.